Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) - Total Liabilities
Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) has total liabilities worth CN¥347.84 Million CNY (≈ $50.90 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Wuhan Easy Diagnosis Biomedicine Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Total Liabilities Trend (2011–2025)
This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Wuhan Easy Diagnosis Biomedicine Co Ltd .
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AGI Greenpac Limited
NSE:AGI
|
India | Rs-24.07 Billion |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
USA | $34.57 Million |
|
Zhejiang Sf Oilless Bearing Co Ltd
SHE:300817
|
China | CN¥259.79 Million |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥147.30 Million |
|
Csd Water Service Co Ltd
SHG:603903
|
China | CN¥2.33 Billion |
|
Movado Group Inc
NYSE:MOV
|
USA | $227.09 Million |
|
Cachet Pharmaceutical Co Ltd
SHE:002462
|
China | CN¥6.02 Billion |
|
China National Complete Plant Import & Export Corp Ltd
SHE:000151
|
China | CN¥2.10 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 002932 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below shows the annual total liabilities of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥324.56 Million ≈ $47.49 Million |
-43.50% |
| 2024-12-31 | CN¥574.40 Million ≈ $84.05 Million |
-47.52% |
| 2023-12-31 | CN¥1.09 Billion ≈ $160.16 Million |
-54.76% |
| 2022-12-31 | CN¥2.42 Billion ≈ $353.99 Million |
+326.64% |
| 2021-12-31 | CN¥567.02 Million ≈ $82.97 Million |
+81.87% |
| 2020-12-31 | CN¥311.77 Million ≈ $45.62 Million |
+1267.39% |
| 2019-12-31 | CN¥22.80 Million ≈ $3.34 Million |
-7.14% |
| 2018-12-31 | CN¥24.55 Million ≈ $3.59 Million |
+80.49% |
| 2017-12-31 | CN¥13.60 Million ≈ $1.99 Million |
-38.35% |
| 2016-12-31 | CN¥22.07 Million ≈ $3.23 Million |
+18.84% |
| 2015-12-31 | CN¥18.57 Million ≈ $2.72 Million |
+62.54% |
| 2014-12-31 | CN¥11.42 Million ≈ $1.67 Million |
+12.05% |
| 2013-12-31 | CN¥10.19 Million ≈ $1.49 Million |
+215.27% |
| 2012-12-31 | CN¥3.23 Million ≈ $473.19K |
+67.03% |
| 2011-12-31 | CN¥1.94 Million ≈ $283.30K |
-- |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more